Overcoming Resistance to the THZ series of covalent transcriptional CDK inhibitors. Gao Y, Zhang T, Terai H, Ficarro SB, Kwiatkowski N, Hao MF, Sharma B, Christensen CL, Chipumuro E, Wong KK, Marto JA, Hammerman PS, Gray NS, George RE. 2018 Feb;25(2):135-142.e5. doi: 10.1016/j.chembiol.2017.11.007. Epub 2017 Dec 21.
Super-Enhancer-Driven Transcriptional dependencies in Cancer. Sengupta S, George RE. 2017 Apr;3(4):269-281. doi: 10.1016/j.trecan.2017.03.006. Epub 2017 Apr 12.
Cbx3/HP1γ deficiency confers enhanced tumor-killing capacity on CD8+ T cells. Sun M, Ha N, Pham DH, Frederick M, Sharma B, Naruse C, Asano M, Pipkin ME, George RE, Thai TH. 2017 Feb; 7:42888. doi: 10.38/srep42888. Read it
Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis. Carter DR, Sutton SK, Pajic M, Murray J, Sekyere EO, Fletcher J, Beckers A, De Preter K, Speleman F, George RE, Haber M, Norris MD, Cheung BB, Marshall GM. 2016 Jun; 10(6):866-78. doi: 10.1016/j.molonc.201606.004. Epub 2016 Mar 2. Read it
Targeting ALK: The Ten Lives of a Tumor. Versteeg R, George RE. Cancer Discov. 2016 Jan;6(1):20-1. doi: 10.1158/2159-8290.CD-15-1411. Read it
TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Valentijn LJ, Koster J, Zwijnenburg DA, Hasselt NE, van Sluis P, Volckmann R, van Noesel MM, George RE, Tytgat GA, Molenaar JJ, Versteeg R. Nat Genet. 2015 Dec;47(12):1411-4. doi: 10.1038/ng.3438. Epub 2015 Nov 2. Read it
ALK inhibitor resistance in ALKF1174L-driven neuroblastoma is associated with AXL activation and induction of EMT. Debruyne DN, Bhatnagar N, Sharma B, Luther W, Moore NF, Cheung NK, Gray NS, George RE. Oncogene. 2015 Nov 30. doi: 10.1038/onc.2015.434 [Epub ahead of print]. Read it
Seek and Ye Shall Find: Subclonal Anaplastic Lymphoma Kinase Mutations. George RE. Clin Cancer Res. 2015 Nov 1;21(21):4747-9. doi: 10.1158/1078-0432.CCR-15-1397. Epub 2015 Sep 11. Read it
A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Krishnadas DK, Shusterman S, Bai F, Diller L, Sullivan JE, Cheerva AC, George RE, Lucas KG. Cancer Immunol Immunother. 2015 Oct;64(10):1251-60. doi: 10.1007/s00262-015-1731-3. Epub 2015 Jun 24. Read it
Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, Chipumuro E, Herter-Sprie GS, Akbay EA, Altabef A, Zhang J, Shimamura T, Capelletti M, Reibel JB, Cavanaugh JD, Gao P, Liu Y, Michaelsen SR, Poulsen HS, Aref AR, Barbie DA, Bradner JE, George RE, Gray NS, Young RA, Wong KK. Cancer Cell. 2014 Dec 8;26(6):909-22. doi: 10.1016/j.ccell.2014.10.019. Erratum in: Cancer Cell. 2015 Jan 12;27(1):149. Read it
CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer. Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, Abraham BJ, Sharma B, Yeung C, Altabef A, Perez-Atayde A,Wong KK, Yuan GC, Gray NS, Young RA, George RE. Cell. 2014 2014 Nov 20;159(5):1126-39. doi: 10.1016/j.cell.2014.10.024. Epub 2014 Nov 6. Read it
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblatoma. Moore NF, Azarova AM, Bhatnagar N, Ross KN, Drake LE, Frumm S, Liu QS, Christie AL, Sanda T, Chesler L, Kung AL, Gray NS, Stegmaier K, George RE. Oncotarget. 2014 Sep 30;5(18):8737-49. Read it
Intrinsic susceptibility MRI identifies tumors with ALK F1174L mutation in genetically-engineered murine models of high-risk neuroblastoma. Jamin Y, Glass L, Hallsworth A, George R, Koh DM, Pearson AD, Chesler L, Robinson SP. PLoS One. 2014 Mar 25;9(3):e92886. doi: 10.1371/journal.pone.0092886. eCollection 2014. Read it
Mutations that disrupt PHOXB interaction with the neuronal calcium sensor HPCAL1 impede cellular differentiation in neuroblastoma. Wang W, Zhong Q, Teng L, Bhatnagar N, Sharma B, Zhang X, Luther W 2nd, Haynes LP, Burgoyne RD, Vidal M, Volchenboum S, Hill DE, George RE. Oncogene. 2014 June 19;33(25):3316-24. doi: 10.1038/onc.2013.290. Epub 2013 Jul 22. Read it
Distinct neuroblastoma-associated alterations of PHOX2B impair sympathetic neuronal differentiation in zebrafish models. Pei D, Luther W, Wang W, Paw BH, Stewart RA, George RE. PLoS Genet. 2013 Jun;9(6):e1003533. doi: 10.1371/journal.pgen.1003533. Epub 2013 Jun 6. Read it
The ALK F1174L mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A, Ahmad Z, Barker K, Moreau L, Webber H, Wang W, Liu Q, Perez-Atayde A, Rodig S, Cheung NK, Raynaud F, Hallberg B, Robinson SP, Gray NS, Pearson AD, Eccles SA, Chesler L, George RE. Cancer Cell, 2012 Jul 10; 22(1):117-30. Read it
Promising therapeutic targets in neuroblastoma. Matthay KK, George RE, Yu AL. Clinical Cancer Research, 2012 May 15; 18(10):2740-53. Read it
Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Zhu S, Lee JS, Guo F, Shin J, Perez-Atayde AR, Kutok JL, Rodig SJ, Neuberg DS, Helman D, Feng H, Stewart RA, Wang W, George RE, Kanki JP, Look AT. Cancer Cell, 2012 Mar 20; 21(3):362-73. Read it
Tumor histology during induction therapy in patients with high-risk neuroblastoma. George RE, Perez-Atayde AR, Yao X, London WB, Shamberger RC, Neuberg D, Diller L. Pediatric Blood and Cancer, 2012 Sep; 59(3):506-10. Read it
Emerging importance of ALK in neuroblastoma. Azarova AM, Gautam G, George RE. Seminars in Cancer Biology, 2011 Oct; 21(4):267-75. Read it
Discovery of 3,5-Diamino-1,2,4-triazole ureas as potent anaplastic lymphoma kinase inhibitors. Deng X, Wang J, Zhang J, Sim T, Kim ND, Sasaki T, Luther W, George RE, Jänne PA, Gray NS. ACS Medicinal Chemistry Letters, 2011 May 12; 2(5):379-84. Read it
Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children’s Oncology Group study. George RE, Lahti JM, Adamson PC, Zhu K, Finkelstien D, Ingle AM, Reid JM, Krailo M, Neuberg D, Blaney SM, Diller L. Pediatric Blood and Cancer, 2010 Oct; 55(4):629-38. Read it
Pharmacotherapy of neuroblastoma. George RE, Diller L, Bernstein ML. Expert Opinion on Pharmacotherapy, 2010 Jun; 11(9):1467-78. Read it
Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide SNP array analysis. Volchenboum SL, Li C, Li S, Attiyeh EF, Reynolds CP, Maris JM, Look AT, George RE. Cancer Research, 2009 May 15; 69(10):4143-9. Read it
Activating mutations in ALK provide a therapeutic target in neuroblastoma. George RE, Sanda T, Hanna M, Fröhling S, Luther W, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L, Greulich H, Morris SW, Meyerson M, Look AT. Nature, 2008 Oct 16; 455(7215):975-8. Read it
Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C, Fox EA, Meyerson M, Diller L, Fortino P, Look AT, Maris JM. PLoS One, 2007 Feb 28; 2(2):e255. Read it
Does MYCN amplification manifested as homogenously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children’s Oncology Group study. Moreau LA, McGrady P, London WB, Shimada H, Cohn SL, Maris JM, Diller L, Look AT, George RE. Clinical Cancer Research, 2006 Oct 1; 12(19):5693-7. Read it
High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger RC, Pulsipher M, Grupp SA, Diller L. Journal of Clinical Oncology, 2006 Jun 20;24(18):2891-6. Read it
Zebrafish foxd3 is selectively required for neural crest specification, migration and survival. Stewart RA, Arduini BL, Berghmans S, George RE, Kanki JP, Henion PD, Look AT. Developmental Biology, 2006 Apr 1; 292(1):174-88. Read it
Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months of age with disseminated neuroblastoma: a Pediatric Oncology Group Study. George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, Brodeur GM, Castleberry RP, Look AT. Journal of Clinical Oncology, 2005 Sep 20; 23(27):6466-73. Read it
Super-Enhancer-Driven Transcriptional dependencies in Cancer. Sengupta S, George RE. 2017 Apr;3(4):269-281. doi: 10.1016/j.trecan.2017.03.006. Epub 2017 Apr 12.
Cbx3/HP1γ deficiency confers enhanced tumor-killing capacity on CD8+ T cells. Sun M, Ha N, Pham DH, Frederick M, Sharma B, Naruse C, Asano M, Pipkin ME, George RE, Thai TH. 2017 Feb; 7:42888. doi: 10.38/srep42888. Read it
Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis. Carter DR, Sutton SK, Pajic M, Murray J, Sekyere EO, Fletcher J, Beckers A, De Preter K, Speleman F, George RE, Haber M, Norris MD, Cheung BB, Marshall GM. 2016 Jun; 10(6):866-78. doi: 10.1016/j.molonc.201606.004. Epub 2016 Mar 2. Read it
Targeting ALK: The Ten Lives of a Tumor. Versteeg R, George RE. Cancer Discov. 2016 Jan;6(1):20-1. doi: 10.1158/2159-8290.CD-15-1411. Read it
TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Valentijn LJ, Koster J, Zwijnenburg DA, Hasselt NE, van Sluis P, Volckmann R, van Noesel MM, George RE, Tytgat GA, Molenaar JJ, Versteeg R. Nat Genet. 2015 Dec;47(12):1411-4. doi: 10.1038/ng.3438. Epub 2015 Nov 2. Read it
ALK inhibitor resistance in ALKF1174L-driven neuroblastoma is associated with AXL activation and induction of EMT. Debruyne DN, Bhatnagar N, Sharma B, Luther W, Moore NF, Cheung NK, Gray NS, George RE. Oncogene. 2015 Nov 30. doi: 10.1038/onc.2015.434 [Epub ahead of print]. Read it
Seek and Ye Shall Find: Subclonal Anaplastic Lymphoma Kinase Mutations. George RE. Clin Cancer Res. 2015 Nov 1;21(21):4747-9. doi: 10.1158/1078-0432.CCR-15-1397. Epub 2015 Sep 11. Read it
A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Krishnadas DK, Shusterman S, Bai F, Diller L, Sullivan JE, Cheerva AC, George RE, Lucas KG. Cancer Immunol Immunother. 2015 Oct;64(10):1251-60. doi: 10.1007/s00262-015-1731-3. Epub 2015 Jun 24. Read it
Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, Chipumuro E, Herter-Sprie GS, Akbay EA, Altabef A, Zhang J, Shimamura T, Capelletti M, Reibel JB, Cavanaugh JD, Gao P, Liu Y, Michaelsen SR, Poulsen HS, Aref AR, Barbie DA, Bradner JE, George RE, Gray NS, Young RA, Wong KK. Cancer Cell. 2014 Dec 8;26(6):909-22. doi: 10.1016/j.ccell.2014.10.019. Erratum in: Cancer Cell. 2015 Jan 12;27(1):149. Read it
CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer. Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, Abraham BJ, Sharma B, Yeung C, Altabef A, Perez-Atayde A,Wong KK, Yuan GC, Gray NS, Young RA, George RE. Cell. 2014 2014 Nov 20;159(5):1126-39. doi: 10.1016/j.cell.2014.10.024. Epub 2014 Nov 6. Read it
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblatoma. Moore NF, Azarova AM, Bhatnagar N, Ross KN, Drake LE, Frumm S, Liu QS, Christie AL, Sanda T, Chesler L, Kung AL, Gray NS, Stegmaier K, George RE. Oncotarget. 2014 Sep 30;5(18):8737-49. Read it
Intrinsic susceptibility MRI identifies tumors with ALK F1174L mutation in genetically-engineered murine models of high-risk neuroblastoma. Jamin Y, Glass L, Hallsworth A, George R, Koh DM, Pearson AD, Chesler L, Robinson SP. PLoS One. 2014 Mar 25;9(3):e92886. doi: 10.1371/journal.pone.0092886. eCollection 2014. Read it
Mutations that disrupt PHOXB interaction with the neuronal calcium sensor HPCAL1 impede cellular differentiation in neuroblastoma. Wang W, Zhong Q, Teng L, Bhatnagar N, Sharma B, Zhang X, Luther W 2nd, Haynes LP, Burgoyne RD, Vidal M, Volchenboum S, Hill DE, George RE. Oncogene. 2014 June 19;33(25):3316-24. doi: 10.1038/onc.2013.290. Epub 2013 Jul 22. Read it
Distinct neuroblastoma-associated alterations of PHOX2B impair sympathetic neuronal differentiation in zebrafish models. Pei D, Luther W, Wang W, Paw BH, Stewart RA, George RE. PLoS Genet. 2013 Jun;9(6):e1003533. doi: 10.1371/journal.pgen.1003533. Epub 2013 Jun 6. Read it
The ALK F1174L mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A, Ahmad Z, Barker K, Moreau L, Webber H, Wang W, Liu Q, Perez-Atayde A, Rodig S, Cheung NK, Raynaud F, Hallberg B, Robinson SP, Gray NS, Pearson AD, Eccles SA, Chesler L, George RE. Cancer Cell, 2012 Jul 10; 22(1):117-30. Read it
Promising therapeutic targets in neuroblastoma. Matthay KK, George RE, Yu AL. Clinical Cancer Research, 2012 May 15; 18(10):2740-53. Read it
Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Zhu S, Lee JS, Guo F, Shin J, Perez-Atayde AR, Kutok JL, Rodig SJ, Neuberg DS, Helman D, Feng H, Stewart RA, Wang W, George RE, Kanki JP, Look AT. Cancer Cell, 2012 Mar 20; 21(3):362-73. Read it
Tumor histology during induction therapy in patients with high-risk neuroblastoma. George RE, Perez-Atayde AR, Yao X, London WB, Shamberger RC, Neuberg D, Diller L. Pediatric Blood and Cancer, 2012 Sep; 59(3):506-10. Read it
Emerging importance of ALK in neuroblastoma. Azarova AM, Gautam G, George RE. Seminars in Cancer Biology, 2011 Oct; 21(4):267-75. Read it
Discovery of 3,5-Diamino-1,2,4-triazole ureas as potent anaplastic lymphoma kinase inhibitors. Deng X, Wang J, Zhang J, Sim T, Kim ND, Sasaki T, Luther W, George RE, Jänne PA, Gray NS. ACS Medicinal Chemistry Letters, 2011 May 12; 2(5):379-84. Read it
Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children’s Oncology Group study. George RE, Lahti JM, Adamson PC, Zhu K, Finkelstien D, Ingle AM, Reid JM, Krailo M, Neuberg D, Blaney SM, Diller L. Pediatric Blood and Cancer, 2010 Oct; 55(4):629-38. Read it
Pharmacotherapy of neuroblastoma. George RE, Diller L, Bernstein ML. Expert Opinion on Pharmacotherapy, 2010 Jun; 11(9):1467-78. Read it
Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide SNP array analysis. Volchenboum SL, Li C, Li S, Attiyeh EF, Reynolds CP, Maris JM, Look AT, George RE. Cancer Research, 2009 May 15; 69(10):4143-9. Read it
Activating mutations in ALK provide a therapeutic target in neuroblastoma. George RE, Sanda T, Hanna M, Fröhling S, Luther W, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L, Greulich H, Morris SW, Meyerson M, Look AT. Nature, 2008 Oct 16; 455(7215):975-8. Read it
Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C, Fox EA, Meyerson M, Diller L, Fortino P, Look AT, Maris JM. PLoS One, 2007 Feb 28; 2(2):e255. Read it
Does MYCN amplification manifested as homogenously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children’s Oncology Group study. Moreau LA, McGrady P, London WB, Shimada H, Cohn SL, Maris JM, Diller L, Look AT, George RE. Clinical Cancer Research, 2006 Oct 1; 12(19):5693-7. Read it
High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger RC, Pulsipher M, Grupp SA, Diller L. Journal of Clinical Oncology, 2006 Jun 20;24(18):2891-6. Read it
Zebrafish foxd3 is selectively required for neural crest specification, migration and survival. Stewart RA, Arduini BL, Berghmans S, George RE, Kanki JP, Henion PD, Look AT. Developmental Biology, 2006 Apr 1; 292(1):174-88. Read it
Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months of age with disseminated neuroblastoma: a Pediatric Oncology Group Study. George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, Brodeur GM, Castleberry RP, Look AT. Journal of Clinical Oncology, 2005 Sep 20; 23(27):6466-73. Read it
